Get the Stockscreener App
6.29
4.26%
-0.28
Aura Biosciences Inc stock is traded at $6.29, with a volume of 129.43K.
It is down -4.26% in the last 24 hours and up +6.79% over the past month.
Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.
See More
Previous Close:
$6.57
Open:
$6.55
24h Volume:
129.43K
Relative Volume:
0.45
Market Cap:
$411.09M
Revenue:
-
Net Income/Loss:
$-76.41M
P/E Ratio:
-3.276
EPS:
-1.92
Net Cash Flow:
$-64.56M
1W Performance:
+3.11%
1M Performance:
+6.79%
6M Performance:
-25.21%
1Y Performance:
-11.78%
1-Day Range:
$6.24
$6.59
1-Week Range:
$5.92
$6.675
52-Week Range:
$4.345
$12.38
Aura Biosciences Inc Stock (AURA) Company Profile
Name
Aura Biosciences Inc
Sector
Industry
Phone
(617)500-8864
Address
80 GUEST STREET, BOSTON
Compare AURA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AURA
Aura Biosciences Inc
|
6.29 | 411.09M | 0 | -76.41M | -64.56M | -1.92 |
|
VRTX
Vertex Pharmaceuticals Inc
|
443.40 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
521.00 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
318.25 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
560.04 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.49 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Aura Biosciences Inc Stock (AURA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-28-25 | Resumed | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | H.C. Wainwright | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Outperform |
| Apr-17-23 | Resumed | BTIG Research | Buy |
| Jul-19-22 | Initiated | JMP Securities | Mkt Outperform |
Aura Biosciences Inc Stock (AURA) Latest News
Aura Biosciences Holds 2025 Annual Stockholders Meeting - TipRanks
Non-Muscle Invasive Bladder Cancer Market Set to Grow Substantially Through 2034, DelveInsight Projects | CG Oncology, Pfizer, UroGen Pharma, Janssen Research & Development, LLC, Protara Therapeutics - The Globe and Mail
Harbor Capital Advisors Inc. Takes Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
PTC Brings Cloud-Native Model-Based Definition to Onshape - The Globe and Mail
Company News for Jun 13, 2025 - The Globe and Mail
Bank of America Corp DE Increases Stock Holdings in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Two Sigma Investments LP Reduces Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Kantar appoints Jeff Greenspoon as CEO, Americas - The Globe and Mail
Kernaghan buying at Western Forest Products (WEF) - The Globe and Mail
BNP Paribas Financial Markets Invests $50,000 in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
15,427 Shares in Aura Biosciences, Inc. (NASDAQ:AURA) Acquired by ProShare Advisors LLC - Defense World
Ameriprise Financial Inc. Has $704,000 Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Option Volatility And Earnings Report For June 26 - The Globe and Mail
Learn to Evaluate (AURA) using the Charts - news.stocktradersdaily.com
Brokers Set Expectations for AURA Q2 Earnings - Defense World
Deutsche Bank AG Buys 15,951 Shares of Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
Aura Biosciences, Inc. (NASDAQ:AURA) Receives Average Recommendation of “Buy” from Analysts - Defense World
Equities Analysts Offer Predictions for AURA FY2028 Earnings - Defense World
Aura Biosciences (NASDAQ:AURA) Raised to Buy at HC Wainwright - Defense World
H.C. Wainwright sets $22 target for Aura Biosciences stock By Investing.com - Investing.com Canada
Aura Biosciences (AURA) Receives 'Buy' Rating from HC Wainwright & Co. | AURA Stock News - GuruFocus
H.C. Wainwright sets $22 target for Aura Biosciences stock - Investing.com
Aura Biosciences assumed with a Buy at H.C. Wainwright - TipRanks
AURA: Analyst Initiates Buy Rating with $22 Price Target | AURA Stock News - GuruFocus
Innovative Precision Oncology and Promising Clinical Results Justify Buy Rating for Aura Biosciences Inc - TipRanks
Aura Biosciences (NASDAQ:AURA) Earns Market Outperform Rating from JMP Securities - Defense World
Northern Trust Corp Has $3.18 Million Stock Position in Aura Biosciences, Inc. (NASDAQ:AURA) - Defense World
JMP maintains $19 target on Aura Biosciences stock after FDA insights - Investing.com Canada
AURA: JMP Securities Reiterates Market Outperform Rating | AURA Stock News - GuruFocus
Strategic Positioning and Regulatory Advantage Bolster Aura Biosciences Inc’s Buy Rating - TipRanks
Finance Watch: Public Company Fundraising Sank Across The Board In Q1 - insights.citeline.com
Anthony Gibney Buys 721% More Aura Biosciences Shares - simplywall.st
Long Term Trading Analysis for (AURA) - news.stocktradersdaily.com
Aura Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Major Stock Moves: Aura Biosciences Inc Sees Insider Buying Spree! - TipRanks
Promising Developments and Strategic Advancements Propel Aura Biosciences Inc’s Buy Rating - TipRanks
Aura Biosciences Advances in Cancer Therapy Trials - TipRanks
Aura Biosciences Raises $69.9 Million in Public Offering - TipRanks
Aura Biosciences announces public offering; shares down - MSN
Aura Biosciences: Strategic Advancements and Clinical Progress Drive Buy Rating - TipRanks
FDA lifts hold on Scynexis trial; Incyte’s Zynyz notches another FDA approval - Endpoints News
Aura Biosciences Reports First Quarter 2025 Financial Results and Business Highlights - GlobeNewswire
Aura Biosciences Launches Public Offering Of Common Stock And Warrants - Nasdaq
Aura Biosciences announces common stock, warrant offering, no amount given - TipRanks
Aura Biosciences Prices $75 Million Offering of Shares, Warrants - marketscreener.com
Aura Biosciences sets terms for $75 million public offering By Investing.com - Investing.com India
Aura Biosciences sets terms for $75 million public offering - Investing.com Australia
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - GlobeNewswire
Aura Biosciences Announces Pricing of Public Offering of Common Stock and Warrants - Benzinga
Aura Biosciences Secures $75M Funding: Major Push for Precision Cancer Treatment Development - Stock Titan
Aura Biosciences Launches Proposed Public Offering of Shares, Warrants - marketscreener.com
Aura Biosciences Inc Stock (AURA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aura Biosciences Inc Stock (AURA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Johnson David Michael | Director |
May 16 '25 |
Buy |
4.90 |
20,000 |
98,000 |
166,167 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Buy |
4.90 |
50,000 |
245,000 |
58,452 |
| Gibney Anthony S | See Remarks |
May 16 '25 |
Sale |
5.15 |
1,519 |
7,823 |
56,933 |
1.02%
1.78%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):